JP2018505899A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505899A5
JP2018505899A5 JP2017543785A JP2017543785A JP2018505899A5 JP 2018505899 A5 JP2018505899 A5 JP 2018505899A5 JP 2017543785 A JP2017543785 A JP 2017543785A JP 2017543785 A JP2017543785 A JP 2017543785A JP 2018505899 A5 JP2018505899 A5 JP 2018505899A5
Authority
JP
Japan
Prior art keywords
alzheimer
disease
mammal
condition
cognitive dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543785A
Other languages
English (en)
Japanese (ja)
Other versions
JP6830895B2 (ja
JP2018505899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018305 external-priority patent/WO2016134042A2/en
Publication of JP2018505899A publication Critical patent/JP2018505899A/ja
Publication of JP2018505899A5 publication Critical patent/JP2018505899A5/ja
Application granted granted Critical
Publication of JP6830895B2 publication Critical patent/JP6830895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543785A 2015-02-18 2016-02-17 ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン Active JP6830895B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117888P 2015-02-18 2015-02-18
US62/117,888 2015-02-18
PCT/US2016/018305 WO2016134042A2 (en) 2015-02-18 2016-02-17 Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau

Publications (3)

Publication Number Publication Date
JP2018505899A JP2018505899A (ja) 2018-03-01
JP2018505899A5 true JP2018505899A5 (https=) 2019-03-14
JP6830895B2 JP6830895B2 (ja) 2021-02-17

Family

ID=56692299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543785A Active JP6830895B2 (ja) 2015-02-18 2016-02-17 ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン

Country Status (8)

Country Link
US (2) US10618899B2 (https=)
EP (1) EP3259274B1 (https=)
JP (1) JP6830895B2 (https=)
KR (1) KR102220260B1 (https=)
CN (1) CN107709326B (https=)
AU (1) AU2016220049C1 (https=)
CA (1) CA2976258C (https=)
WO (1) WO2016134042A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
EP3969639B1 (en) 2019-05-13 2025-03-12 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
ES2932481B2 (es) * 2021-07-09 2023-09-11 Consejo Superior Investigacion Compuestos inhibidores de la quinasa de tau y tubulina (ttbk)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
EP1012151B1 (en) * 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
CA2398956A1 (en) 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害(mci)および関連障害の処置方法
US11325904B2 (en) 2011-08-02 2022-05-10 Buck Institute For Research On Aging Tropinol esters and related compounds to promote normal processing of APP
WO2013026021A2 (en) 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
EP2903436B1 (en) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
US20140371283A1 (en) 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘

Similar Documents

Publication Publication Date Title
JP2017075173A5 (https=)
MX2024010140A (es) Nuevos metodos.
AR110747A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
JP2017057230A5 (https=)
JP2018021046A5 (https=)
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
JP2014507446A5 (https=)
JP2011509252A5 (https=)
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
RU2017105353A (ru) Соединения
JP2016522254A5 (https=)
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2016512817A5 (https=)
JP2017518982A5 (https=)
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2016501219A5 (https=)
JP2015537009A5 (https=)
JP2018505899A5 (https=)
JP2015516419A5 (https=)
RU2017139002A (ru) Пироглутамат вортиоксетина
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016537432A5 (https=)
RU2018122012A (ru) БИС-пиридазиновые соединения и их применение в лечении рака
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
RU2019110264A (ru) Циклическое соединение